Pharmaceuticals are generally classified as generic drugs or new drugs, while some new drugs are also classified as long-listed drugs. These latter drugs are new drugs with expired patents but, because they have been used over many years in clinical practice, much expertise exists regarding their safety and usage.
Further, according to healthcare professionals, experience and research have indicated that some of these medicines may have indications other than those for which they were originally intended.
Like new medicines, these drugs await development for use against diseases for which no particularly effective medicines are available.
To discover similar new uses for our long-listed drugs, the Company is supporting research through collaboration with external agencies.

Soleton (Zaltoprofen)

Research on this drug’s effects on patients of diffuse-type tenosynovial giant cell tumors (pigmented villonodular synovitis) and of localized-type tenosynovial giant cell tumors (giant cell tumors of tendon sheath) is progressing, mainly at Kanazawa University Hospital.

Calvan (Bevantolol)

Research on this drug as a therapeutic medicine for Huntington’s disease is underway at the Spanish company SOM Innovation Biotech, S.L.


Business Development We are interested in any opportunities of collaboration, partnering or licensing of our pipeline products and welcome any proposal on them. If you have any interest in any of our pipeline products, please contact our business development team bd@chemiphar.co.jp.
Related Information

Business Development Contact

If you have any interest in our pipeline, please contact our business development team bd@chemiphar.co.jp.

Get ADOBE® READER®

NOTICE
To view our PDF files, you need Adobe Reader software installed on your local drive. The Adobe Reader can be downloaded by clicking on this icon.

PageTop